胃电刺激对胃电节律紊乱的作用

背景:胃电刺激已成为一种潜在的治疗胃动力障碍性疾病的方法。目的:观察、比较单导联和两导联长脉冲胃电刺激对胃电节律紊乱和呕吐相关样症状的作用。方法:以静脉滴注垂体后叶素(一种血管加压素)建立犬胃动力紊乱模型,将多导电刺激器与胃浆膜电极相连,输入最佳刺激参数以控制胃慢波,评估盐水组、垂体后叶素组和单导联、两导联胃电刺激组在静脉滴注生理盐水或垂体后叶素的30min里的症状评分并全程记录四导联胃肌电活动。结果:垂体后叶素能诱导胃电节律紊乱和呕吐相关样症状(P<0.05)。单导联和两导联长脉冲胃电刺激均能纠正胃电节律紊乱(P<0.01),但对呕吐相关样症状无明显缓解作用(P>0.05)。两导联胃电刺激纠正胃电节律紊乱的最佳刺激能量(320ms×mA±43ms×mA)显著低于单导联胃电刺激(2 750ms×mA±186ms×mA)(P<0.01)。结论:单导联和两导联长脉冲胃电刺激能纠正垂体后叶素诱导的胃电节律紊乱,但不能缓解呕吐相关样症状。两导联胃电刺激控制胃慢波所需的刺激能量较单导联胃电刺激低。     

胃节律紊乱患者的胃运动

目的 估价胃节律紊乱患者的胃运动状态。 方法 体表胃电图(EGG)示胃节律紊乱的患者30例,分为胃节律过速、胃节律过缓和胃节律不齐3组。在内镜下测定餐后胃窦部蠕动压,并与10例健康人进行对照。然后给予口服吗丁啉每次20 mg,每日3次,4周后复查EGG。 结果 胃节律过速时胃窦部运动指数最低(0.18±0.15,对照组为5.98±1.57,P<0.01);其次是胃节律过缓(1.28±0.78,对照组为5.98±1.57,P<0.01);而胃节律不齐可有较高的运动指数(3.15±1.66,对照组为5.98±1.57,P<0.05)。服吗丁啉后,各类型的胃节律紊乱得到不同程度的纠正,随之胃运动也得到显著改善。 结论 不同类型的胃肌电紊乱是导致不同程度的胃运动低下的重要原因。     

胃节律紊乱综合征的研究进展

正常人体胃的基本胃节律(BER)来自胃大弯上部的起步点(Pacemaker),呈整齐而规则的慢波经胃体、胃窦纵环肌向幽门方向传播,频率约3 cpm.BER是恒定不变和始终存在的[1,2].     

胃节律紊乱综合征及其治疗

至1989.6月止,对2520例患者作了胃电图检查,检出胃节律紊乱综合征(GDS)192例,占7.6％,本征的诊断应包括临床表现和特征性的胃电图表现.近年我们采用模拟胃生物电治疗仪及吗叮啉治疗,在缓解症状及恢复胃节律方面均取得初步成效.     

5-HT及电刺激对胃节律紊乱模型新西兰白兔胃电活动的影响

目的:观察5-HT及电刺激对胃节律紊乱模型新西兰白兔胃电活动的影响.方法:对以胰高血糖素造模的新西兰白兔胃节律紊乱模型采用外周注射5-HT、胃起步点起搏,电刺激室旁核和中缝大核(P7)的方法,四导胃浆膜电信号同步记录,分析胃体、及胃窦部胃电信号的平均频率,相位差,负相位比率,波形对应率,幅度等指标,考察5-HT,及电刺...     

胃节律紊乱综合征的胆囊运动研究

目的：为了研究胃节律紊乱综合征患者的胆囊运动。方法：用99mTc放射性核素序列显像法对29例胃节律紊乱综合征（GastricdysrhythmasyndormeGDS）患者检测胃排空的同时对其空腹和餐后胆囊排空运动进行了前瞻性研究．并与15例正常人进行比较。在口服多潘立酮治疗之后，23例胃节律紊乱纠正的患者，重复上述检查．结果：GDS患者的胃、空腹和餐后胆囊排空分数明显低于正常对照组（P均＜0．01）。多潘立酮治疗后胃节律紊乱纠正的患者，在其胃运动障碍纠正的同时，空腹和餐后胆囊排空分数显著性提高（P均＜0．01），而与正常人比较，差异无显著性（P均＞0．05）。结论：GDS患者在男运动障碍的同时存在着胆囊运动障碍。     

胃电节律失常的研究进展

自1974年Code首次报道了犬胃电节律失常以来,国内外学者对胃电节律失常进行了大量的动物实验及临床研究.本文就胃电节律失常的特点,发生机制,病理生理,临床意义及治疗等方面作一综述.     

中药治疗胃节律紊乱综合征的疗效

目的观察自拟中药方治疗胃节律紊乱综合征的疗效.方法本组病例95例,符合上腹胀痛、恶心和(或)呕吐、早饱或厌食,甚至体重减轻,有关检查无明显异常.胃电图餐后振幅变异系数在33%以上,均列为研究对象.中医诊断参照<中医内科学>五版教材"胃痛”和"呕吐”肝气犯胃证型.随机分为两组.中药组55例,男14例,女41例;年龄43.7岁±18.1岁;病程17.0mo±14.2mo.均服用自拟中药方,药有香附、柴胡、木香、白芍、陈皮、半夏、青皮等.上药水煎每日服一剂,早晚空腹温服.西药对照组40例,其中男9例,女31例,年龄38.7岁±16.7岁;病程11.0mo±23.1mo.服用吗叮啉片10mg～20mg,3次/d.治疗期间,停服其他任何药物.症状消失或服药4wk后复查胃电图结果中药组治愈(症状消失、胃电振幅变异系数<20%)35例(67.3%);显效(主要症状消失、变异系数<25%)11例;好转(部分症状消失或好转、变异系数25%～30%)9例;总有效率100%.西药组治愈16例(40%),显效10例,好转8例,无效6例,总有效率85%.中药组治愈率、总有效率均高于西药组(P<0.05和P<0.01).结论自拟中药方治疗胃节律紊乱综合征有良好的疗效.     

莫沙比利联合穴位针刺治疗糖尿病胃轻瘫的临床疗效观察

目的探讨莫沙必利联合穴位针刺治疗糖尿病胃轻瘫的临床疗效。方法 182例确诊为糖尿病胃轻瘫患者随机分为3组,给予莫沙必利治疗62例、单纯穴位针刺治疗54例、莫沙必利联合穴位针刺治疗66例,3组均治疗8周,随访1年,观察临床疗效及临床症状复发情况并进行比较分析。结果莫沙必利联合穴位针刺治疗糖尿病胃轻瘫疗效明显优于单用莫沙必利和穴位针刺组,而且临床症状复发率明显低于其它2组,两项比较均具有统计学意义（P〈0.05）。结论莫沙必利联合穴位针刺治疗糖尿病胃轻瘫具有较好的近期疗效与远期疗效,是值得选择和推广的治疗方法。     

Study of the regulatory effect of acupuncture on rotation-induced gastric dysrhythmia in rabbits

AIM: A model of experimental gastric dysrhythmia in rabbits was set up to evaluate the effect of different acupoints on regulating gastric dysrhythmia in rabbits so as to promote acupuncture treatment for this kind of disease.METHODS: A model of gastric dysrhythmia in rabbits was established by the rotation method using the basic electrical rhythm (BER) as an objective index. After puncturing at the points of Zusanli (ST36), Neiguan (PC6), Tiaokou (ST38) and Tianquan (PC2) in the four groups of experimental gastric dysrhythmia rabbits, the difference in regulatory effects on the disturbance and frequency of the gastric electric slow wave was observed.RESULTS: Before needling at the specific acupoints Zusanli and Neiguan, the percentage of disturbance electric slow wave for the Zusanli and Neiguan groups was 57.0785 ± 10.644 and 55.5173 ± 6.0500, respectively; after such needling, the percentage was 43.7823 ± 10.1518 and 43.5147 ± 6.8983 for the Zusanli and Neiguan groups, respectively, while the frequency of electric slow wave for the Zusanli and Neiguan groups was 2.2870 ± 0.3800 and 2.4020 ± 0.3536, respectively, before needling and after needling, the frequency was 2.7090 ± 0.5865 and 2.9220 ± 0.4923 for the Zusanli and Neiguan groups, respectively. Comparing the percentage and frequency for the Zusanli and Neiguan groups before and after needling, the result shows that both groups have a significant difference statistically (P < 0.05) but between the Zusanli and Neiguan groups, there was no significant difference. Before and after needling the nonspecific acupoints of Tiaokou and Tianquan, there was no difference between the Tiaokou and Tianquan groups. Between the Zusanli and Tiaokou groups and the Neiguan and Tianquan groups, there are significant differences in regulating gastric dysrhythmia.CONCLUSION: This model is suitable for the observation of gastric dysrhythmia. The specific acupoints of Zusanli and Neiguan have good effects on the treatment of gastric dysrhythmia.     

针刺功能性消化不良患者足三里穴对其胃运动功能的影响

目的针刺功能性消化不良（functional dyspepsia，FD）患者足三里穴（ST36），采用胃电测定和胃排空测定的方法，观察胃运动的变化，为临床治疗提供依据。方法根据罗马Ⅲ标准，确定FD患者。预先测定FD患者进餐前、后胃电活动的变化和B超测定胃排空，采用针刺FD患者双侧足三里穴（连续3d），再测定进餐前、后胃电活动的变化，以及B超测定胃排空，观察针刺FD患者足三里穴对其胃动力作用的影响。同时设立健康志愿对照组。结果FD患者在进餐前后，胃电活动呈现不规律的电活动改变。胃的排空呈现减慢趋势。与正常对照组相比，存在显著性差异。而给予针刺足三里后，患者胃电活动逐渐趋于规律，且胃排空较未针刺状况相比，明显加快，接近于正常对照组。结论针刺FD患者足三里穴，可以调节FD患者胃电节律紊乱，改善胃排空障碍。     

血管生成抑制剂抗胃癌微淋巴管生成的实验研究

Objective To evaluate the inhibitory effect of 2-(8-hydroxy-6-methoxy-1-oxo-1-H-2-benzopyran-3-Y1) propionic acid (NM-3) on lymphangiogenesis in gastric cancer using orthotopic implantated tumor models of BALB/C nude mice. Methods A BALB/C nude mouse model of transplanted in situ human gastric cancer was established. Twenty-eight nude mice were divided into four groups with 7 each: control group, NM-3 treated group, carboplatin (10 mg/kg) treated group,and NM-3 combiantion group injected with normal saline, 5 mg/kg of NM-3, 10 mg/kg of carboplatin or 5 mg/kg of NM-3, + 10 mg/kg carboplatin, respectively, twice a week for 8 weeks. At the end of the 8th week, all mice were sacrificed for detection of lymphatic microvessel density (LMVD),lymphatic vessel endothelial hyaluranic acid receptor 1 (LYVE-1), podoplanin and Prox-1 byimmunohistochemistry with staining. Results In comparison with control group, the LYVE-1 level in other three groups was decreased with no significant difference (P＞ 0.05). The concentrations of podoplanin and Prox-1 in NM-3 group and combination group decreased significantly than those in control group and carboplatin group (P ＜ 0.05). The number of LMVD in NM-3 group and combination group was 4.72±0.50 and 4.78± 0.38, respectively, which was significantly lower than that in control group (7.35±0.55)and carboplatin group (6.98i0.35, P＜0.05). Conclusion The NM-3 can inhibit the growth of gastric cancer by interfering lymphangiogenesis of gastric cancer.     

血管生成抑制剂抗胃癌微淋巴管生成的实验研究

Objective To evaluate the inhibitory effect of 2-(8-hydroxy-6-methoxy-1-oxo-1-H-2-benzopyran-3-Y1) propionic acid (NM-3) on lymphangiogenesis in gastric cancer using orthotopic implantated tumor models of BALB/C nude mice. Methods A BALB/C nude mouse model of transplanted in situ human gastric cancer was established. Twenty-eight nude mice were divided into four groups with 7 each: control group, NM-3 treated group, carboplatin (10 mg/kg) treated group,and NM-3 combiantion group injected with normal saline, 5 mg/kg of NM-3, 10 mg/kg of carboplatin or 5 mg/kg of NM-3, + 10 mg/kg carboplatin, respectively, twice a week for 8 weeks. At the end of the 8th week, all mice were sacrificed for detection of lymphatic microvessel density (LMVD),lymphatic vessel endothelial hyaluranic acid receptor 1 (LYVE-1), podoplanin and Prox-1 byimmunohistochemistry with staining. Results In comparison with control group, the LYVE-1 level in other three groups was decreased with no significant difference (P＞ 0.05). The concentrations of podoplanin and Prox-1 in NM-3 group and combination group decreased significantly than those in control group and carboplatin group (P ＜ 0.05). The number of LMVD in NM-3 group and combination group was 4.72±0.50 and 4.78± 0.38, respectively, which was significantly lower than that in control group (7.35±0.55)and carboplatin group (6.98i0.35, P＜0.05). Conclusion The NM-3 can inhibit the growth of gastric cancer by interfering lymphangiogenesis of gastric cancer.     

牛磺酸对三硝基苯磺酸诱导的结肠炎大鼠肠纤维化的抑制作用

目的 探讨牛磺酸对三硝基苯磺酸(TNBS)诱导的结肠炎大鼠肠纤维化的影响.方法 32只SD大鼠均分为对照组、模型组、低剂量和高剂量牛磺酸组.对照组以0.9%氯化钠溶液灌肠,其余3组以TNBS灌肠诱导建立结肠炎模型.低剂量和高剂量牛磺酸组于造模前1周每日分别给予牛磺酸400和800 mg/kg干预,直至造模结束.观察大鼠临床表现及疾病活动指数(DAI),行结肠大体评分和组织学评分,检测大鼠结肠长度、结肠重量.测定结肠组织中羟脯氨酸(Hyp)、Ⅰ型胶原蛋白、转化生长因子-β1(TGF-β1)蛋白和mRNA、Smad3蛋白和mRNA水平.结果 与对照组相比,模型组大鼠体重减轻、DAI评分升高、结肠狭窄伴近端扩张、结肠长度缩短、结肠重量增加、大体评分也显著升高(P<0.01).牛磺酸干预后,大鼠体重、DAI评分、结肠长度等指标均有所改善.模型组纤维化评分为1.88±0.35.较对照组明显增加(0.25±0.46,P<0.01);低剂量和高剂量牛磺酸组纤维化评分分别为1.25±0.71和0.75±0.47,较模型组下降(P<0.05).模型组大鼠结肠Hyp、TGF-β1、Ⅰ型胶原蛋白、Smad3蛋白和mRNA含量均较低剂量和高剂量牛磺酸组明显上升(P值均<0.05).结论 牛磺酸能有效抑制TNBS诱导的结肠炎大鼠肠纤维化,其抗纤维化机制可能与下调TGF-β1、抑制TGF-β/Smad3通路有关,为解决克罗恩病肠纤维化和肠狭窄提供一定的实验依据.     

丹参对兔视网膜光损伤保护作用的实验观察

目的观察丹参对兔眼光损伤视网膜的保护作用方法健康青紫兰兔8只，随机分为对照组、实验组，每组4只。在循环光环境适应7d，光照前暗适应24h：散大瞳孔至8mm后，14500lx光照30min，然后暗适应30min，在光照后1h，对照组静脉推注0．85％生理盐水20ml；实验组静脉推注丹参注射液20ml（冻干粉1．0g／kg＋0．85％生理盐水）。光照后48h取视网膜制成超薄切片，电镜观察视网膜形态结构变化。结果实验组视网膜组织结构清楚，细胞形态规整，对照组光感受器外节膜盘崩解非常明显，外核层细胞排列紊乱，核固缩．色素上皮层细胞核染色质边集，呈现细胞凋亡的早期改变，线粒体空泡变性。结论丹参对兔眼光损伤视网膜具有保护作用。     

硫代乙酰胺致大鼠肠源性内毒素血症模型探讨

目的 探讨不同剂量硫代乙酰胺(TAA)所制备的大鼠肠源性内毒素血症(IETM)模型的量效关系.方法 将40只大鼠分为4组,每组10只.TAA组分别以200、400、600mg/kg剂量的TAA灌胃,24h后相同剂量TAA重复灌胃一次,建立不同剂量TAA致大鼠IETM的动物模型;健康对照组以等体积0.9%氯化钠溶液灌胃.观察造模后24、48h大鼠死亡情况,48h后采集存活大鼠腹主动脉血,检测血浆内毒素、血清ALT和AST,观察肝组织病理变化.采用单因素方差分析,组间比较采用t检验.结果 造模48h后,健康对照组无大鼠死亡,200mg/kgTAA模型组死亡2只,400mg/kg TAA模型组死亡5只,600mg/kg TAA模型组死亡8只.200、400、600mg/kg TAA模型组大鼠血清ALT水平分别为(305.09±116.78)、(901.67±274.31)和(1454.84±473.49)U/L,明显高于健康对照组的(47.81±22.61)U/L(t=14.583、25.896、20.596,均P＜0.05);200、400、600mg/kg TAA模型组大鼠血清AST水平分别为(465.88±139.96)、(884.37±250.90)和(1889.23±159.67)U/L,明显高于健康对照组的(69.33±22.04)U/L(t=12.988、18.455、13.542,均P＜0.05);200、400、600mg/kg TAA模型组大鼠血浆内毒素水平分别为(0.436±0.110)、(0.550±0.095)和(0.620±0.057)EU/mL,明显高于健康对照组的(0.103±0.056)EU/mL(t=7.335、5.260、8.191,均P＜0.05).病理学显示不同剂量TAA模型组有不同程度的肝细胞变性坏死.结论 TAA剂量为200～600mg/kg时可成功制作IETM模型,200mg/kg TAA模型组大鼠死亡率较低,适于进一步的实验研究.     

血管生成抑制剂抗胃癌微淋巴管生成的实验研究

目的 通过建立未分化人胃腺癌SGC-7901原位移植裸鼠模型,应用2-(8-羟基-6-甲氧基-1-氧-1-氢-2-苯并吡喃-3-羟基)丙酸(NM-3)和卡铂的腹腔化学治疗,观察其对裸鼠原位移植人胃癌微淋巴管生成的影响.方法 建立人胃癌SGC-7901原位种植BALB/C裸鼠模型28只,随机分为4组,每组7只,分别腹腔内注射0.9%氯化钠溶液、NM-3(10 mg/kg)、卡铂(5 mg/kg)和NM-3+卡铂,2次/周.8周后处死裸鼠,采用定量免疫组化染色检测淋巴管内皮细胞透明质酸受体(LYVE)-1、肾小球足突细胞膜黏蛋白、同源异型盒转录因子(Prox)-1;计数微淋巴管密度(LMVD)值.结果 卡铂组、NM-3组及NM-3+卡铂组LYVE-1表达值均较0.9%氯化钠溶液组下降,但差异无统计学意义(P值均＞0.05);NM-3组及NM-3+卡铂组肾小球足突细胞黏蛋白、Prox-1值较0.9%氯化钠溶液组及卡铂组均显著下降(P＜0.05).NM-3组及NM-3+卡铂组LMVD值分别为4.72±0.50和4.78±0.38,较0.9%氯化钠溶液组及卡铂组均显著下降[7.35±0.55和6.98±0.35,P＜0.05].结论 NM-3能抑制胃癌微淋巴管生成,抑制肿瘤的生长和转移.